Multidrug-resistant Gram-negative infections: what are the treatment options? (Q35002302)

5 August 2017

1 reference

title

Multidrug-resistant Gram-negative infections: what are the treatment options? (English)

1 reference

5 August 2017

Gram-negative bacteria

0 references

multiple drug resistance

1 reference

Helen Giamarellou

1

1 reference

PubMed ID

19747006

5 August 2017

Garyphallia Poulakou

series ordinal

2

1 reference

5 August 2017

1 October 2009

1 reference

5 August 2017

1 reference

5 August 2017

69

1 reference

5 August 2017

14

1 reference

5 August 2017

1879-1901

1 reference

https://scigraph.springernature.com/pub.10.2165/11315690-000000000-00000

5 August 2017

0 references

cites work

Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.2165%2F11315690-000000000-00000

In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11315690-000000000-00000

Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11315690-000000000-00000

Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11315690-000000000-00000

Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11315690-000000000-00000

Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11315690-000000000-00000

Beta-lactam-fosfomycin antagonism involving modification of penicillin-binding protein 3 in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11315690-000000000-00000

Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.

21 January 2018

1 reference

12 December 2020

Toxicity after prolonged (more than four weeks) administration of intravenous colistin

1 reference

12 December 2020

Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B.

1 reference

12 December 2020

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

1 reference

12 December 2020

Use of Parenteral Colistin for the Treatment of Serious Infection Due to Antimicrobial-Resistant Pseudomonas aeruginosa

1 reference

12 December 2020

Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae

1 reference

12 December 2020

Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone

1 reference

12 December 2020

In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy

1 reference

12 December 2020

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases

1 reference

12 December 2020

Administration of antibiotics via the respiratory tract as monotherapy for pneumonia

1 reference

12 December 2020

Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii

1 reference

12 December 2020

Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.

1 reference

12 December 2020

Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).

1 reference

12 December 2020

Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

1 reference

12 December 2020

Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia

1 reference

12 December 2020

Systemic colistin use in children without cystic fibrosis: a systematic review of the literature

1 reference

12 December 2020

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections

1 reference

12 December 2020

Aerosolized antibiotics to treat ventilator-associated pneumonia

1 reference

12 December 2020

Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation.

1 reference

12 December 2020

Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens

1 reference

12 December 2020

Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem

1 reference

12 December 2020

Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis

1 reference

12 December 2020

Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.

1 reference

12 December 2020

Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).

1 reference

12 December 2020

Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies

1 reference

12 December 2020

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence

1 reference

12 December 2020

Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii

1 reference

12 December 2020

Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents

1 reference

12 December 2020

In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis

1 reference

12 December 2020

Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster

1 reference

12 December 2020

Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

1 reference

12 December 2020

In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures

1 reference

12 December 2020

Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes

1 reference

12 December 2020

Fosfomycin trometamol

1 reference

12 December 2020

AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus–Acinetobacter baumannii complex

1 reference

12 December 2020

In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

1 reference

12 December 2020

Comparative study of fosfomycin activity in Mueller-Hinton media and in tissues

1 reference

12 December 2020

Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece).

1 reference

12 December 2020

Activities of beta-lactams, fluoroquinolones, amikacin and fosfomycin alone and in combination against Pseudomonas aeruginosa isolated from complicated urinary tract infections

1 reference

12 December 2020

Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint

1 reference

12 December 2020

Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients

1 reference

12 December 2020

Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.

1 reference

12 December 2020

MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli

1 reference

12 December 2020

In vitro and in vivo potency of polymyxin B against IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa

1 reference

12 December 2020

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae

1 reference

12 December 2020

Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae

1 reference

12 December 2020

Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study

1 reference

12 December 2020

In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii.

1 reference

12 December 2020

Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program

1 reference

12 December 2020

In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii

1 reference

12 December 2020

Treatment options for multidrug-resistant bacteria.

1 reference

12 December 2020

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

1 reference

12 December 2020

In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides

1 reference

12 December 2020

Old polymyxins are back: is resistance close?

1 reference

12 December 2020

Tigecycline pharmacokinetic/pharmacodynamic update

1 reference

12 December 2020

Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens

1 reference

12 December 2020

Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients

1 reference

12 December 2020

Tigecycline for the treatment of Acinetobacter infections: a case series

1 reference

12 December 2020

BSAC standardized disc susceptibility testing method.

1 reference

12 December 2020

Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

1 reference

12 December 2020

Antibacterial spectrum of fosfomycin trometamol

1 reference

12 December 2020

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

1 reference

12 December 2020

In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.

1 reference

12 December 2020

Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug‐Resistant Pseudomonas aeruginosa and Acinetobacter baumannii

1 reference

12 December 2020

In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae

1 reference

12 December 2020

Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

1 reference

12 December 2020

In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals

1 reference

12 December 2020

In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates

1 reference

12 December 2020

Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation

1 reference

12 December 2020

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

1 reference

12 December 2020

In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates

1 reference

12 December 2020

Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies

1 reference

12 December 2020

Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.

1 reference

12 December 2020

In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth.

1 reference

12 December 2020

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients

1 reference

12 December 2020

Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.

1 reference

12 December 2020

Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06.

1 reference

12 December 2020

Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside

1 reference

12 December 2020

Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit

1 reference

12 December 2020

Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents

1 reference

12 December 2020

Tigecycline: a new glycylcycline antimicrobial agent

1 reference

12 December 2020

Target site penetration of fosfomycin in critically ill patients

1 reference

12 December 2020

A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline

1 reference

12 December 2020

Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections

1 reference

12 December 2020

AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii

1 reference

12 December 2020

Ventilator-associated pneumonia due to colistin susceptible-only microorganisms.

1 reference

12 December 2020

RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae.

1 reference

12 December 2020

Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria

1 reference

12 December 2020

Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic.

1 reference

12 December 2020

Stability of doripenem in vitro in representative infusion solutions and infusion bags

1 reference

12 December 2020

1 reference

12 December 2020

Rapid development of Acinetobacter baumannii resistance to tigecycline

1 reference

12 December 2020

Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.

1 reference

12 December 2020

Synergy testing of multidrug resistant Acinetobacter baumanii against tigecycline and polymyxin using an E-test methodology

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent

1 reference

12 December 2020

In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group

1 reference

12 December 2020

EUCAST technical note on tigecycline

1 reference

12 December 2020

Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients

1 reference

12 December 2020

Antimicrobial activity of fosfomycin against multidrug-resistant Pseudomonas aeruginosa in vitro

1 reference

12 December 2020

In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.

1 reference

12 December 2020

Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii

1 reference

12 December 2020

Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa

1 reference

12 December 2020

Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis

1 reference

12 December 2020

Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study

1 reference

12 December 2020

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

1 reference

12 December 2020

Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study

1 reference

12 December 2020

Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model.

1 reference

12 December 2020

Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections

1 reference

12 December 2020

Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City

1 reference

12 December 2020

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

1 reference

12 December 2020

Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report

1 reference

12 December 2020

Comparison of three standardized disc susceptibility testing methods for colistin.

1 reference

12 December 2020

Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential

1 reference

12 December 2020

Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases

1 reference

12 December 2020

Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin

1 reference

12 December 2020

Colistin susceptibility testing by Etest and disk diffusion methods

1 reference

12 December 2020

Colistin heteroresistance in acinetobacter and its association with previous colistin therapy

1 reference

12 December 2020

Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin

1 reference

12 December 2020

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

1 reference

12 December 2020

Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis

1 reference

12 December 2020

The pharmacokinetics of colistin in patients with cystic fibrosis

1 reference

12 December 2020

In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens

1 reference

12 December 2020

Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa

1 reference

12 December 2020

Tigecycline: a new glycylcycline for treatment of serious infections

1 reference

12 December 2020

Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance

1 reference

12 December 2020

Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review

1 reference

12 December 2020

Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE

1 reference

12 December 2020

The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America

1 reference

12 December 2020

Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii

1 reference

12 December 2020

Multidrug-resistant Klebsiella pneumoniae mediastinitis safely and effectively treated with prolonged administration of tigecycline.

1 reference

12 December 2020

Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS.

1 reference

12 December 2020

Fosfomycin: use beyond urinary tract and gastrointestinal infections

1 reference

12 December 2020

Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline

1 reference

12 December 2020

Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies

1 reference

12 December 2020

Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock

1 reference

12 December 2020

Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model

1 reference

12 December 2020

Comité de l'Antibiogramme de la Société Française de Microbiologie report 2003

1 reference

12 December 2020

Toxicity of Colistin in Cystic Fibrosis Patients

1 reference

12 December 2020

Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment

1 reference

12 December 2020

Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study

1 reference

12 December 2020

Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens

1 reference

12 December 2020

Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study

1 reference

12 December 2020

10.2165/11315690-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

19747006

Dimensions Publication ID

5 August 2017

0 references

1 reference

PubMed ID

19747006